APA (7th ed.) Citation

A, K., RR, W., KL, W., SJ, L., Y, T., D, A., . . . MC, G. (2021). Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. The Journal of rheumatology, 48(8), 1230. https://doi.org/10.3899/jrheum.201183

Chicago Style (17th ed.) Citation

A, Kavanaugh, et al. "Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs." The Journal of Rheumatology 48, no. 8 (2021): 1230. https://doi.org/10.3899/jrheum.201183.

MLA (9th ed.) Citation

A, Kavanaugh, et al. "Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs." The Journal of Rheumatology, vol. 48, no. 8, 2021, p. 1230, https://doi.org/10.3899/jrheum.201183.